Conclusões

As opções de Teste de Risco Fetal DLE têm como objetivo identificar o risco de gestação afetada em grávidas de todas as idades.

Os resultados das gestantes submetidas aos testes são comparados aos dados obtidos de uma população de grávidas brasileiras, com vistas a tornar os testes eficientes na nossa realidade, evitando comparações com grávidas de países com composição étnica diferente do Brasil (Europa e Estados Unidos).

São utilizadas combinações de marcadores e escolhidos níveis de corte, que delimitam os testes positivos, com o objetivo de maximizar a detecção de gestações afetadas e minimizar tanto a ansiedade provocada por um teste positivo em uma gestação não-afetada quanto o número de gestantes submetidas a procedimentos invasivos.

O Laboratório DLE disponibiliza sua Assessoria Científica, composta por profissionais preparados, para esclarecer dúvidas técnicas e sobre interpretação de laudos.

Para informações sobre credenciamento, parcerias, materiais para divulgação e ou coleta fale com o Canal do Cliente.

Referências Bibliográficas

1. BIAGIOTTI R, BRIZZI L, PERITI E, D'AGATA A, VANZI E, CARIATI E. First trimester screening for Down's syndrome using maternal serum PAPP-A and free beta-hCG in combination with fetal nuchal translucency thickness. Br J Obstet Gynaecol 105:917-920, 1998.

2. BOGART M, PANDIAN MR, JONES OW. Abnormal maternal serum chorionic gonadotropin levels in pregnancies with fetal chromosome abnormalities. Prenatal Diagnosis 7:623-630, 1987.

3. BRAMBATI B, MACINTOSH MC, TEISNER B, MAGUINESS S, SHRIMANKER K, LANZANI A, BONACCHI I, TULUI L, CHARD T, GRUDZINSKAS JG. Low maternal serum levels of pregnancy associated plasma protein A (PAPP-A) in the first trimester in association with abnormal fetal karyotype. Br J Obstet Gynaecol 100:324-326, 1993.

4. BRIZOT ML, SNIJDERS RJ, BERSINGER NA, KUHN P, NICOLAIDES KH. Maternal serum pregnancy-associated plasma protein A and fetal nuchal translucency thickness for the prediction of fetal trisomies in early pregnancy. Obstet Gynecol 84:918-922, 1994.

5. BRIZOT ML, SNIJDERS RJ, BUTLER J, BERSINGER NA, NICOLAIDES KH. Maternal serum hCG and fetal nuchal translucency thickness for the prediction of fetal trisomies in the first trimester of pregnancy. Br J Obstet Gynaecol 102:127-132, 1995.

6. BROCK DJH, BOLTON AE, MONAGHAN JM. Prenatal diagnosis of anencephaly through maternal serum alpha-fetoprotein measurement. Lancet ii:923, 1973.

7. BROCK DJH, SUTCLIFFE RG. Alpha-fetoprotein in the antenatal diagnosis of anencephaly and spina bifida. Lancet ii:197-199,1972.

8. CANICK J, KNIGHT GJ, PALOMAKI GE, HADDOW JE, CUCKLE HS, WALD NJ. Low second trimester maternal serum unconjugated oestriol in pregnancies with Down's syndrome. Brit J Obstet Gynaecol 95:330-333, 1988.

9. CUCKLE HS, WALD NJ, LINDENBAUM RH. Maternal serum alpha-fetoprotein measurement. A screening test for Down Syndrome. Lancet i:926-929, 1984.

10. CUCKLE HS. Screening for neural tube defects. Ciba Found Symp 181:253-266, 1994.

11. HINO M, KOKI Y, NISHI S. Nimpu ketsu naka no alpha-fetoprotein. Igaku No Ayumi 82:512, 1972.

12. MERKATZ IR, NITOWSKY HM, MACRI JN, JOHNSON WE. An association between low maternal serum alpha-fetoprotein and fetal chromosomal abnormalities. Am J Obstet Gynecol 148:886-894, 1984.

13. MILUNSKY A, ALPERT E. Results and benefits of a maternal serum alpha-fetoprotein screening program. JAMA. 252:1438-1442, 1984.

14. NICOLAIDES KH, BRIZOT ML, SNIJDERS RJ. Fetal nuchal translucency: ultrasound screening for fetal trisomy in the first trimester of pregnancy. Br J Obstet Gynaecol 101:782-786, 1994.

15. NICOLAIDES KH, SEBIRE NJ, SNIJDERS RJM. 11-14 Week Scan: The Diagnosis Of Fetal Abnormalities. Carnforth, UK: Parthenon Publishing, 1999.

16. NORGAARD-PEDERSEN B, BAGGER P, BANG J, FISCHER-RASMUSSEN W, GAD C, HASCH E, HELKJAER PE, JACOBSEN JC, KJELDSEN J, KJAERSGAARD E, et al. Maternal-serum-alphafetoprotein screening for fetal malformations in 28 062 pregnancies. A four-year experience from a low-risk area. Acta Obstet Gynecol Scand 64:511-514, 1985.

17. ORLANDI F, DAMIANI G, HALLAHAN TW, KRANTZ DA, MACRI JN. First-trimester screening for fetal aneuploidy: biochemistry and nuchal translucency. Ultrasound Obstet Gynecol 10:381-386, 1997.

18. PENROSE LS. The relative effects of paternal and maternal age in mongolism. J Genet 27:219, 1933.

19. SNIJDERS RJ, SUNDBERG K, HOLZGREVE W, HENRY G, NICOLAIDES KH. Maternal age- and gestation-specific risk for trisomy 21. Ultrasound Obstet Gynecol 13:167-70, 1999.

20. SPENCER K, LIAO AW, SKENTOU H, CICERO S, NICOLAIDES KH. Screening for triploidy by fetal nuchal translucency and maternal serum free beta-hCG and PAPP-A at 10-14 weeks of gestation. Prenat Diagn 20:495-499, 2000.

21. SPENCER K, ONG C, SKENTOU H, LIAO AW, H NICOLAIDES K. Screening for trisomy 13 by fetal nuchal translucency and maternal serum free beta-hCG and PAPP-A at 10-14 weeks of gestation. Prenat Diagn 20:411-416, 2000.

22. SPENCER K, SOUTER V, TUL N, SNIJDERS R, NICOLAIDES KH. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A. Ultrasound Obstet Gynecol 13:231-237, 1999.

23. SPENCER K, TUL N, NICOLAIDES KH. Maternal serum free beta-hCG and PAPP-A in fetal sex chromosome defects in the first trimester. Prenat Diagn 20:390-394, 2000.

24. TUL N, SPENCER K, NOBLE P, CHAN C, NICOLAIDES K. Screening for trisomy 18 by fetal nuchal translucency and maternal serum free beta-hCG and PAPP-A at 10-14 weeks of gestation. Prenat Diagn 19:1035-1042, 1999.

25. WALD NJ, KENNARD A, HACKSHAW A, MCGUIRE A. Antenatal screening for Down's syndrome. J Med Screen 4:181-246, 1997.

26. WALD NJ, RODECK C, HACKSHAW AK, WALTERS J, CHITTY L, MACKINSON AM; SURUSS RESEARCH GROUP. First and second trimester antenatal screening for Down's syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS). Health Technol Assess 7:1-77, 2003.

27. WALD NJ, WATT HC, HACKSHAW AK. Integrated screening for Down's syndrome on the basis of tests performed during the first and second trimesters. N Engl J Med 341:461-467, 1999.

28. ZIMMERMANN R, HUCHA A, SAVOLDELLI G, BINKERT F, ACHERMANN J, GRUDZINSKAS JG. Serum parameters and nuchal translucency in first trimester screening for fetal chromosomal abnormalities. Br J Obstet Gynaecol 103:1009-1014, 1996.

 

Busca DLE

Solicitação
de material

CANAL DO CLIENTE

4020-8080
Seg. a Sex. das 08h às 18h
Este endereço de e-mail está protegido contra spambots. Você deve habilitar o JavaScript para visualizá-lo.



Nossas unidades

 

 

 

 
   

Certificações

Controles de Qualidade